Jason Zemansky
Stock Analyst at B of A Securities
(4.88)
# 62
Out of 5,182 analysts
55
Total ratings
76.92%
Success rate
40.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $8 → $9 | $3.52 | +155.68% | 6 | Mar 30, 2026 | |
| INSM Insmed | Maintains: Buy | $211 → $213 | $135.17 | +57.58% | 12 | Mar 24, 2026 | |
| LGND Ligand Pharmaceuticals | Initiates: Buy | $244 | $231.27 | +5.50% | 1 | Mar 11, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Buy | $34 | $9.66 | +252.15% | 1 | Mar 2, 2026 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $6 | $1.88 | +219.15% | 1 | Jan 21, 2026 | |
| KROS Keros Therapeutics | Maintains: Neutral | $18 → $19 | $11.51 | +65.07% | 3 | Nov 28, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $17 → $26 | $25.50 | +1.96% | 6 | Nov 28, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $8 → $7 | $0.81 | +761.01% | 6 | Nov 18, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $52 → $56 | $65.32 | -14.27% | 5 | Oct 2, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $40.50 | -23.46% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $29 | $9.26 | +213.17% | 2 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $31 | $21.39 | +44.93% | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $2.9 → $2.5 | $1.91 | +30.89% | 5 | Jun 20, 2024 |
Rocket Pharmaceuticals
Mar 30, 2026
Maintains: Buy
Price Target: $8 → $9
Current: $3.52
Upside: +155.68%
Insmed
Mar 24, 2026
Maintains: Buy
Price Target: $211 → $213
Current: $135.17
Upside: +57.58%
Ligand Pharmaceuticals
Mar 11, 2026
Initiates: Buy
Price Target: $244
Current: $231.27
Upside: +5.50%
Eikon Therapeutics
Mar 2, 2026
Initiates: Buy
Price Target: $34
Current: $9.66
Upside: +252.15%
Inhibikase Therapeutics
Jan 21, 2026
Initiates: Buy
Price Target: $6
Current: $1.88
Upside: +219.15%
Keros Therapeutics
Nov 28, 2025
Maintains: Neutral
Price Target: $18 → $19
Current: $11.51
Upside: +65.07%
Arcus Biosciences
Nov 28, 2025
Maintains: Neutral
Price Target: $17 → $26
Current: $25.50
Upside: +1.96%
Werewolf Therapeutics
Nov 18, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $0.81
Upside: +761.01%
Cytokinetics
Oct 2, 2025
Maintains: Neutral
Price Target: $52 → $56
Current: $65.32
Upside: -14.27%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $40.50
Upside: -23.46%
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $9.26
Upside: +213.17%
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $21.39
Upside: +44.93%
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $1.91
Upside: +30.89%